Last updated on October 2020

Prospective Non-interventional Multi-center Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pulmonary Arterial Hypertension | Late Infantile Neuronal Ceroid Lipfuscinsosis | Anemic Cancer | Primary Insulin Hypersecretion | Abdominal Surgery | Gambling Problems | Stasis Dermatitis | Pulmonary Hypertension | Spine Athroplasty | Functional Dyspepsia | Spinocerebellar Disorders | Catheter Complications | Dental Filling | Nerve Injury | Mental Disability | Cancer Prevention | Renal Anemia | Chronic Pelvic Pain | Testotoxikose | Infantile Fibrosarcoma | Memory Problems | Severe Premenstrual Symptom | Complicated Grief | Serial Evaluation of Ductal Epithelium | Recurrent Pregnancy Loss | Indikation: Diabetes - Typ II | Partial Medial Meniscectomy | Pelvic Adhesions | Joint Injuries | Myopic Macular Degeneration | Low Testosterone | Cancer Treatment | Chronic Renal Anemia | Surviving Abuse | Pseudobulbar Affect | Habit Reversal | Open Heart Surgery | Effects of Chemotherapy
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Patients who are treated with Riociguat for PAH

Exclusion Criteria:

  • N/A

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.